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The Microcapillary Protein Crystallization System (MPCS)
embodies a new semi-automated plug-based crystallization
technology which enables nanolitre-volume screening of
crystallization conditions in a plasticware format that allows
crystals to be easily removed for traditional cryoprotection
and X-ray diffraction data collection. Protein crystals grown in
these plastic devices can be directly subjected to in situ X-ray
diffraction studies. The MPCS integrates the formulation of
crystallization cocktails with the preparation of the crystal-
lization experiments. Within microﬂuidic Teﬂon tubing or the
microﬂuidic circuitry of a plastic CrystalCard,  10–20 nl
volume droplets are generated, each representing a
microbatch-style crystallization experiment with a different
chemical composition. The entire protein sample is utilized in
crystallization experiments. Sparse-matrix screening and
chemical gradient screening can be combined in one com-
prehensive ‘hybrid’ crystallization trial. The technology lends
itself well to optimization by high-granularity gradient
screening using optimization reagents such as precipitation
agents, ligands or cryoprotectants.
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1. Introduction
The ﬁeld of structural biology is generating technologies that
increase throughput and efﬁciency each year. Such advances
have initiated a goal to progress from gene to three-dimen-
sional structure in 3 d. In an effort to improve efﬁciency, one
may want to minimize the volume of protein required such
that sufﬁcient material for crystallization screening and opti-
mization can be obtained from cell-free synthesis. With the
‘three-day’ structure goal in mind, the Accelerated Technol-
ogies Center for Gene to 3D Structure (ATCG3D) is engaged
in the development of several technologies to increase efﬁ-
ciency in the gene-to-structure pipeline, including synthetic
gene design (Gene Composer; http://www.genecomposer.net/),
protein crystal imaging (DETECT-X; Emerald BioSystems)
and microﬂuidic nanovolume crystallization (The Micro-
capillary Protein Crystallization System; MPCS). Here, we
describe the ﬁrst working prototype of the MPCS, which
consists of a microsyringe pumping system, the pumping
system’s associated software (MicroPlugger) and plastic
CrystalCards that house the ‘3+1 mixer’ (where reagents are
combined) and microﬂuidic channel (where experiments are
stored). The CrystalCards are manufactured with materials
that enable a balance between X-ray transmission, optical
clarity, moldability, chemical resistance and surface energy.
This system produces diffraction-ready crystals by allowing
crystal extraction from the CrystalCard or in situ X-raydiffraction and structure solution using diffraction data
obtained from samples within the CrystalCard.
2. Background
The underlying technology used to perform microﬂuidic
nanovolume crystallization discussed here was developed at
the University of Chicago (in the ATCG3D-collaborating
Ismagilov laboratory). Aqueous droplets, here called plugs,
form spontaneously by combining microﬂuidic aqueous
streams with an immiscible and biologically inert ﬂuorocarbon
solution (Song et al., 2003; Tice et al., 2003, 2004). Three
separate aqueous streams of protein, buffer and precipitant
ﬂow simultaneously into a single channel, where a controlled
ﬂow of immiscible and biologically inert ﬂuorocarbon breaks
the combined aqueous streams into 10–20 nl microbatch-style
crystallization experiments (Fig. 1a; Zheng et al., 2003; Zheng,
Tice, Roach et al., 2004). The region where the streams
converge is called the ‘3+1 mixer’. The 10–20 nl crystallization
plugs formed at the ‘3+1 mixer’ are incubated and monitored
for crystallization (Fig. 1b). By controlling the ﬂow rates of the
aqueous streams, very ﬁne concentration gradients are
generated over a series of plugs (Fig. 1c), allowing the crys-
tallographer to carefully probe crystallization phase space for
crystal optimization. Plug-based crystallization permits sparse-
matrix screening (Zheng & Ismagilov, 2005; Zheng, Tice &
Ismagilov, 2004) using a pre-formed cartridge of plugs, the
formation of ﬁne concentration gradients (Zheng et al., 2003)
via on-chip formulation of plug composition and a combina-
tion of sparse-matrix and gradient screening termed the
‘hybrid method’ (Li et al., 2006), the latter of which enables
comprehensive screening of crystallization phase space in one
single crystallization trial. Plug-based microﬂuidic crystal-
lization has also been used to probe scientiﬁc questions
regarding protein-crystal nucleation and growth (Chen et al.,
2005; Zheng et al., 2005; Gerdts et al., 2006) and to generate
crystals for novel protein structures (Gerdts et al., 2006).
3. The MPCS
As a technology development center,ATCG3D hasdeveloped
the Microcapillary Protein Crystallization System (MPCS) in
order to make plug-based protein-crystallization technology
available to the scientiﬁc community. The MPCS instru-
mentation is composed of three essential parts (Fig. 2): (i) a
pumping system, (ii) the MicroPlugger control software and
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Figure 2
MPCS components. (a) A picture of the components of the MPCS system.
(b) Screenshots of the operational modes of the MicroPlugger software.
(c) A picture of the MPCS CrystalCard ﬁlled with dyed protein crystals.
(d) A picture of the PDMS/Teﬂon CrystalCard typically used for the
hybrid method.
Figure 1
Plug-based protein crystallization using the MPCS. (a) A microphoto-
graph of crystallization trials in plugs being formed in the CrystalCard.
(b) Dyed protein crystals in the MPCS CrystalCard. (c) A schematic
drawing (left) of a channel containing a smooth pH gradient (right)
generated using a low-pH buffer, a high-pH buffer and a universal pH
indicator.(iii) the CrystalCard. The pumping system is a four-channel
syringe-pump system that delivers precise and continuous
ﬂows to the MPCS CrystalCard. This system allows indepen-
dent control over each channel and can generate extremely
ﬁne gradients. Pumps are controlled by the MicroPlugger
pump-control software (Fig. 2b). The MicroPlugger software
allows the user to control the pump system in four different
operational modes: Prime Mode (for priming the lines),
Constant Mode (for constant-ﬂow experiments), Gradient
Mode (for generation of ﬁne gradients) and Hybrid Mode (for
sparse-matrix screening using the hybrid method). These
operational modes allow the user to perform all MPCS
experiment styles. The third essential component is the
CrystalCard (Figs. 2c and 2d), which is the ‘microﬂuidic chip’
where the aqueous and ﬂuorous solutions come together to
spontaneously form the 10–20 nl plugs at the 3+1 mixer. The
CrystalCard was designed with a hydrophobic surface that
supports the formation of aqueous plugs and contains a long
microﬂuidic capillary for storage and inspection. Access to
diffraction-ready crystals is gained via physical crystal
extraction from the CrystalCard or by in situ X-ray diffraction.
There are two versions of the MPCS CrystalCard: a plastic
CrystalCard and a PDMS/Teﬂon CrystalCard. The plastic
CrystalCard (Fig. 2c) is used primarily for ﬁne-gradient
screening and the PDMS/Teﬂon CrystalCard (Fig. 2d)i s
typically used for hybrid screening and detergent-based
membrane-protein formulations. (The PDMS/Teﬂon Crystal-
Card has the necessary connection schemes and surface
properties to be compatible with hybrid screening and
detergent-based crystallizations.)
Using the pumping system, software and CrystalCards, the
MPCS generates hundreds of distinct crystallization experi-
ments within a few minutes, free from cross-contamination,
using only  5 ml protein solution. The MPCS does not waste
any precious protein, because there is
no dead volume in the system: the
protein sample is aspirated directly into
a Teﬂon needle and then displaced in its
entirety into the CrystalCard. Addi-
tional features of the MPCS include the
ability to perform microﬂuidic seeding
(Gerdts et al., 2006) and the control of
evaporation by controlling the humidity
of the CrystalCard’s storage container
(CrystalCards stored in a humidiﬁed
container remain unchanged for at least
two months).
3.1. MPCS experiment styles
Plugs formed using the MPCS are
microbatch-style crystallization experi-
ments in which protein and crystallizing
agent are combined and incubated
while surrounded by an oil (ﬂuoro-
carbon, FC40; Li et al., 2006; Yadav et
al., 2005). The MPCS facilitates two
styles of crystallization screening: ﬁne-gradient screening and
hybrid screening.
3.1.1. Fine-gradient/optimization screening. The MPCS
gradient mode allows the crystallographer to very ﬁnely scan a
region of crystallization phase space. Since the aqueous
streams used in an MPCS experiment are independently
controlled using the MPCS pumping system and the Micro-
Plugger software, concentration gradients over a series of
plugs are easily formed by changing the ﬂow rates of the
individual streams (Fig. 1c; Zheng et al., 2003). As the preci-
pitant stream decreases in ﬂow rate, the buffer stream
increases in ﬂow rate such that that the sum of the ﬂow rates
remains constant (although the MicroPlugger software allows
the user to design a customized experiment to suit their needs,
including changing the plug size or the sum of the aqueous
ﬂow rates). Using a ﬁne gradient, the crystallization phase
space of a particular protein–precipitant combination can be
carefully interrogated for crystal optimization or mapped out
to show the transition from precipitation to microcrystals to
single crystals (Fig. 3). In the same manner, so-called reverse
screening can be carried out utilizing two crystallization
cocktails that have been found to promote the formation of
crystals (Stura et al., 1994). On-chip formulation of concen-
tration gradients can be used for the optimization of precipi-
tants, ligands, protein partners or cryoprotectants. By reducing
the volume of protein required for crystal optimization, ﬁne-
gradient formation can decrease protein-production require-
ments when crystals of different protein mutants or DNA
complexes are required.
3.1.2. Hybrid screening. Hybrid screening combines on-
chip formulation of gradients with sparse-matrix screening (Li
et al., 2006). Sparse-matrix screening in plugs is achieved by
generating a ‘pre-formed cartridge’ of plugs composed of
different crystallizing agents (Zheng & Ismagilov, 2005). In the
research papers
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Figure 3
Mapping of crystallization phase space using a ﬁne gradient for ribose-phosphate pyrophos-
phokinase. A precipitant gradient demonstrates a smooth transition from precipitation (lower left)
to microcrystalline precipitation (lower right) to microcrystals (middle left) to a few crystals (upper
right) to single crystals (upper left) of ribose-phosphate pyrophosphokinase.hybrid method of the MPCS, the pre-formed cartridge
containing a series of  100 nl plugs ﬂows into one of the three
aqueous inlets of the 3+1 mixer. Using the Hybrid Mode of the
Microplugger software, a concentration gradient of each
crystallizing agent in the pre-formed cartridge is formed by
coordinating the ﬂow-rate change between the pre-formed
plugs and the buffer stream. Performing sparse-matrix and
gradient screening in the same trial allows the MPCS to scan a
substantial portion of crystallization phase space, generating
20–40 individual crystallization experiments at different
concentrations from each pre-formed crystallant plug.
4. Producing diffraction-ready crystals
The MPCS is more than a low-volume protein-crystallization
screening tool: it produces diffraction-ready crystals. The
experimental volumes (10–20 nl; the exact volumes are
dependent on the CrystalCard and the ﬂow rates) are very
small compared with traditional crystallization techniques.
However, 10–20 nl plugs contain enough protein to generate
crystals that are large enough to obtain useful X-ray diffrac-
tion data. Crystals grown in plugs are typically 40–200 mm
along their longest axis (the channel dimensions are 200  
200 mm). Because the crystals are diffraction-ready, it is critical
to have method(s) for obtaining diffraction data without
scaling up the experiment or translating the crystal hit to
another experimental technique. The MPCS offers two
methods for obtaining X-ray diffraction data from crystals
grown in plugs: traditional cryocooling by crystal extraction
and in situ diffraction.
4.1. Protein-crystal extraction from the MPCS CrystalCard
Protein crystals can be extracted directly from individual
plugs in the MPCS CrystalCards. A thin plastic layer is bonded
to the plastic part that contains the microﬂuidic circuitry. This
thin layer has a bond that is designed to be strong enough to
prevent ﬂuid from leaking out of the CrystalCard during the
crystallization trial but weak enough to be manually peeled off
(Figs. 4a and 4b). Additionally, the plugs are retained in the
plastic part containing the microﬂuidic circuitry. After the thin
plastic layer has been peeled back, the crystals are exposed
and the desired crystal(s) are accessible to microtools such as
cryoloops (Figs. 4c and 4d). Two techniques can be used to
remove the crystals for cryoprotection: (i) the crystal(s) can be
scooped out with a cryoloop and placed in the desired cryo-
protectant or (ii)  1 ml of the desired cryoprotectant can be
pipetted on top of the plugs containing crystals so that when
the crystal is scooped out it is already immersed in cryo-
protectant. Using the ﬁrst technique, evaporation of the plugs
is delayed by  5 min by the layer of ﬂuorocarbon oil. Using
the second technique, evaporation of the plugs is delayed for
at least 20 min, providing ample time to extract many crystals.
research papers
Acta Cryst. (2008). D64, 1116–1122 Gerdts et al.   Microcapillary Protein Crystallization System 1119
Figure 4
Extracting diffraction-ready crystals from the MPCS CrystalCard. (a)A
picture of the thin plastic cover being removed from the MPCS
CrystalCard. (b) A picture of the opened MPCS CrystalCard with all
of the crystallization experiments remaining in the plastic part containing
the microﬂuidic circuitry. (c) A microphotograph of a crystal in a plug just
before being scooped out of the CrystalCard with a cryoloop. (d)A
microphotograph of the crystal in the cryoloop.
Table 1
Crystallographic data.
Values in parentheses are for the 2.00–1.90 A ˚ resolution shellfor lysozymeand
the 1.76–1.70 A ˚ shell for methionine-R-sulfoxide reductase.
Lysozyme
Methionine-R-
sulfoxide reductase
Data collection
Unit-cell parameters (A ˚ ) a = b = 79.18,
c = 38.38,
  =   =   =9 0
a = 42.00, b = 45.17,
c = 45.40,   = 88.4,
  = 83.7,   = 69.1
Space group P43212 (No. 96) P1( N o .1 )
Resolution (A ˚ ) 50–1.90 50–1.70
Wavelength (A ˚ ) 0.97950 0.97932
Total reﬂections 54338 118181
Unique reﬂections 10151 32539
hI/ (I)i 11.4 (2.9) 23.1 (2.2)
Rmerge† (%) 13.7 (58.4) 6.8 (42.3)
Completeness (%) 98.8 (98.5) 95.3 (87.4)
Redundancy 5.4 (5.0) 3.6 (3.3)
Wilson B factor (A ˚ 2) 24.1 22.1
Reﬁnement
Resolution (A ˚ ) 50–1.90 50–1.70
Reﬂections (working/test) 9412/480 30828/1650
Rworking/Rfree‡ (%) 19.6/23.0 16.6/19.9
No. of atoms (protein/solvent) 1001/45 2082/180
R.m.s. deviations
Bond lengths (A ˚ ) 0.016 0.015
Bond angles ( ) 1.607 1.408
Average B factor (A ˚ 2)
All atoms 28.8 28.3
Protein 28.5 27.5
Water 35.9 37.0
Coordinate error based
on Rfree (A ˚ )
0.149 0.095
Ramachandran analysis (%)
Most favored (chain A/B) 89.4 91.7/90.8
Additionally allowed (chain A/B) 10.6 7.3/8.3
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity
measured for the ith reﬂection and hI(hkl)i is the average intensity of all reﬂections with
indices hkl.‡ Rworking =
P
hkl
   jFobsðhklÞj   jFcalcðhklÞj
   =
P
hkl jFobsðhklÞj; Rfree is
calculated in an identical manner using 5% of randomly selected reﬂections that were
not included in the reﬁnement.Crystal extraction was used in combination with an MPCS
ﬁne-gradient screen to generate crystals of methionine-
R-sulfoxide reductase (Fig. 5a). Crystals formed in a concen-
tration optimization gradient screen of 30%(v/v)M P D ,
25%(w/v) PEG 1500, 0.1 M acetate pH 4.5. The protein
concentration was 22 mg ml
 1 in 20 mM HEPES pH 7.0,
500 mM NaCl, 5% glycerol, 2 mM DTT. Crystals were
removed from the CrystalCard using a 0.1–0.2 mm cryoloop,
cryocooled (using the crystallant as the cryoprotectant) and
subjected to X-ray diffraction experiments. A 1.7 A ˚ data set
was collected on SBC-CAT beamline 19BM located at the
Advanced Photon Source at Argonne National Laboratories
andthestructure wassubsequentlysolved andreﬁned (Figs.5b
and 5c; Table 1). The ﬁnal coordinates and structure factors
were deposited in the Protein Data Bank (PDB code 3cxk).
4.2. In situ X-ray diffraction
The CrystalCard has been designed to allow in situ X-ray
diffraction. This allows the crystallographer to assess the
quality of the crystals grown before alteration by the cryo-
protection process (Luft et al., 1999; McPherson, 2000; Ng et
al., 2003; Yadav et al., 2005; Lunde et al., 2008) and to collect
data for structure determination from robust crystals. The
CrystalCard is sufﬁciently transparent to X-rays to be
mounted directly onto a goniometer for X-ray diffraction
experiments at room temperature. Additionally, the Crystal-
Card can be translated along its x and y axes to collect data
from multiple crystals for combination to yield complete data
sets. The CrystalCard can be rotated through  75  without
hitting the beamstop. In order to demonstrate this technique,
we mounted a CrystalCard containing lysozyme crystals on a
goiniometer head at NE-CAT beamline 24ID-C located at the
Advanced Photon Source at Argonne National Laboratories
(Fig. 6a) and collected X-ray diffraction data at room
temperature from three crystals in the CrystalCard. A portion
of the electron-density map generated by molecular replace-
ment is shown in Fig. 6(b). Crystallographic data are provided
in Table 1.
5. Materials and methods
5.1. Preparation of the plastic CrystalCard
Plastic CrystalCards were manufactured by injection
molding (Siloam Biosciences Inc.). Plug formation in the
CrystalCard requires a low surface-energy (hydrophobic)
surface. This ensures that the ﬂuorocarbon oil preferentially
wets the walls of the microcapillary. The polycarbonate
CrystalCard arrives from the manufacturer with a high
research papers
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Figure 5
Methionine-R-sulfoxide reductase. (a) A microphotograph of a methionine-R-sulfoxide reductase crystal. (b) Fo   Fc OMIT map contoured at 3  for
Cys residues and a Zn ion. (c) Ribbon diagram of the NCS dimer of methionine-R-sulfoxide reductase from Burkholderia pseudomallei. Zinc ions are
represented as gold spheres and acetate ions in ball-and-stick representation. The structure was deposited as PDB entry 3cxk.surface-energy (hydrophilic) microcapillary surface. To pre-
pare the microcapillary surface for plug formation, Cytonix
PFC 502AFA solution is used to coat the inside of the
microcapillary. Cytonix PFC 502AFA adheres to the poly-
carbonate surface and generates a coating with a surface
energy of 6–10 dyn cm
 1 (1 dyn cm
 1 =1  10
 3 Nm
 1). To
apply the coating, the CrystalCard is ﬁlled from the outlet with
Cytonix 502AFA solution and incubated on ice for 2 h (the
CrystalCard inlets are prone to crack if incubated at higher
temperatures). The 502AFA solution is removed from the
CrystalCard via a vacuum and clean dry air is forced through
the CrystalCard at 34.5 kPa for 1 h. After drying, the Crys-
talCard is cured at 333 K for 1 h and is then ready for use.
5.2. Macro–micro interface
A macro–micro interface connection between the syringes
and the CrystalCard is required for the MPCS to function
properly. A 360 mm inner diameter, 760 mm outer diameter
(ID/OD 360/760) section of Teﬂon tubing is used to connect
the syringe to the CrystalCard. One end of the Teﬂon tubing
slides onto the syringe needle and the other end slides into a
760 mm inner diameter piece of silicon tubing connected to the
plastic CrystalCard. For the PDMS/Teﬂon CrystalCard, holes
are manufactured in the PDMS to allow a tight-ﬁtting seal
with the ID/OD 360/760 Teﬂon tubing.
5.3. Preparation of the hybrid method pre-formed cartridge
(Li et al., 2006)
A 5–10 cm piece of ID/OD 360/760 Teﬂon tubing was
connected to a 50 ml syringe and the other end to a 10 cm piece
of 200 mm inner diameter/230 mm outer diameter (ID/OD
200/230) Teﬂon storage capillary. The connection was sealed
with capillary wax (Hampton Research). The syringe and
tubings were ﬁlled with FC40 (3M) and the syringe was
mounted on a manual aspirator (Stoelting No. 262M=, Wood
Dale, Illinois, USA). The end of the ID/OD 200/230 Teﬂon
storage capillary was dipped into the ﬁrst precipitant and
 150 nl of ﬂuid (15 units on the aspirator) was aspirated. A
 50 nl air bubble (5 units on the aspirator) was aspirated. This
sequence was repeated until all of the desired precipitants (up
to 24) had been aspirated. 2 ml FC40 ( 200 units on the
aspirator) were aspirated into the tubing and the syringe was
placed on the pump for the experiment. The end of the ID/OD
200/230 Teﬂon storage capillary containing the pre-formed
cartridge was connected to the precipitant inlet of the PDMS/
Teﬂon CrystalCard by cutting the channel with a razor blade
and inserting the capillary horizontally. The end of the ID/OD
200/230 Teﬂon storage capillary was inserted into the PDMS
chip (up to the point in the inlet where it becomes tapered)
and sealed using capillary wax.
5.4. Structure determination
Data sets were collected at the Advanced Photon Source:
beamline 19BM at 100 K for methionine-R-sulfoxide reduc-
tase and beamline 24-IDC at room temperature for lysozyme.
Data were integrated and scaled with HKL-2000 (Otwinowski
& Minor, 1997). For the lysozyme structure, intensities were
integrated separately for each of the three data sets using the
MOSFLM package (Leslie, 1992). The structures of lysozyme
and methionine-R-sulfoxide reductase were solved by mole-
cular replacement using MOLREP (Vagin & Teplyakov, 1997)
with PDB entries 1iee and 3cez as the search models,
respectively. Structures were reﬁned with REFMAC5
(Murshudov et al., 1997) and model building was performed
with Coot (Emsley & Cowtan, 2004).
5.5. X-ray absorption of the CrystalCard
A simple test was conducted to analyze the absorption of
X-rays by the CrystalCard. To do this, the beam current in the
ion chamber normalized to the APS ring current (I/I0) was
measured with and without the CrystalCard inserted at a
wavelength of 0.979261 A ˚ (12.66099 keV). I/I0 without the
CrystalCard was 1.91671   10
 6 and I/I0 with the CrystalCard
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Figure 6
In situ diffraction using the MPCS. (a) A picture of the MPCS
CrystalCard mounted on the goniometer head of an X-ray source. (b)
A portion of the electron-density map obtained by combining in situ
diffraction data from three crystals inside the MPCS CrystalCard.(perpendicular to the beam) was 1.5511   10
 6. This consti-
tutes a 19% X-ray absorbance by the CrystalCard.
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